Real-World Outcome and Prognostic Factors of Pazopanib in Advanced Soft Tissue Sarcoma.
Bader AlshamsanAhmad BadranAisha AlshibanyFatma MaraikiMahmoud A ElshenawyTusneem ElhassanJean Paul AtallahPublished in: Cancer management and research (2021)
Pazopanib is an effective treatment for STS. However, it showed variability in the clinical outcome in favor of ASPS and an outstanding response in the DT/AF subtype. Pazopanib-induced hypothyroidism is a good prognostic factor for disease control and is associated with prolonged PFS and OS.